# Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

> **NCT04333147** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 2916 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** Otilimab (GSK3196165)
- **DRUG:** csDMARD(s)

## Key facts

- **NCT ID:** NCT04333147
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-12
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 2916 (ACTUAL)
- **Why stopped:** Study is early terminated due to Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333147, "Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04333147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*